Myriad Genetics RiskScore
Myriad Genetics has launched riskScore, which employs a proprietary algorithm combining analysis of 80 SNPs and patients' personal and family history of cancer to determine a woman's risk of breast cancer. Results from this test will be reported alongside Myriad's myRisk Hereditary Cancer test, a 28-gene panel that gauges patients' risk for for eight cancers. RiskScore will help guide decisions for asymptomatic patients who get negative myRisk results, providing definitive answers to the 90 percent of patients testing negative for hereditary cancer genes, the company noted. Myriad has completed two validation studies in patients of European descent that it will present at upcoming conferences.
Ranomics VariantFind DNA Library Synthesis
Ranomics, a Toronto-based biotechnology firm, has launched VariantFind, a proprietary platform for creating DNA libraries. VariantFind uses multiplexing technology to incorporate a large number of mutagenic oligonucleotides into a single series of PCR reactions to create high-quality and cost-effective variant libraries for use in protein engineering, synthetic biology, and agriculture, the company said. The resulting libraries can be easily integrated into different workflows, Ranomics added.
Intermountain Precision Genomics RxMatch
Intermountain Precision Genomics Core Laboratory launched RxMatch, a new service to enable physicians to implement personalized medicine when prescribing medications. The RxMatch Antidepressant Panel, launched Sept. 5 as part of the new service, will allow physicians to use patients' genomics to find the right antidepressant. The RxMatch Antidepressant Panel will be powered by CNSDose, a company that will provide decision support to Intermountain based on its knowledge of liver and blood-brain-barrier metabolism of antidepressant medications.
For more new products and services, please visit the New Products page on our website.